

**HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC):**  
**NICE TECHNOLOGY APPRAISALS – RECOMMENDED**

NICE TA664 – Liraglutide for managing overweight and obesity in adults, December 2020 <https://www.nice.org.uk/guidance/ta664>

**RED – RECOMMENDED FOR RESTRICTED PRESCRIBING BY SPECIALIST  
MULTIDISCIPLINARY TIER 3 WEIGHT MANAGEMENT SERVICE ONLY.  
NOT RECOMMENDED FOR PRIMARY CARE PRESCRIBING**

NAME: GENERIC (TRADE)	WHAT IT IS	INDICATION	DATE DECISION LAST REVISED	DECISION STATUS	NICE GUIDANCE
Liraglutide (Saxenda®)	Glucagon like peptide-1 (GLP-1) receptor agonist	For managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults.	February 2020  NICE TA replaces local decision from September 2017	Final	NICE TA664 – Recommended

**HMMC recommendation:**

Liraglutide (Saxenda®) is recommended as an option for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults in line with the recommendation in TA664

**RED STATUS**

- **NOT RECOMMENDED FOR PRIMARY CARE PRESCRIBING**
- **RECOMMENDED FOR RESTRICTED PRESCRIBING BY SPECIALIST MULTIDISCIPLINARY TIER 3 WEIGHT MANAGEMENT SERVICE ONLY**

**NICE TA664 recommendations** <https://www.nice.org.uk/guidance/ta664>

Liraglutide is recommended as an option for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults, **only if:**

- they have a body mass index (BMI) of at least 35 kg/m<sup>2</sup> (or at least 32.5 kg/m<sup>2</sup> for members of minority ethnic groups known to be at equivalent risk of the consequences of obesity at a lower BMI than the white population) **and**
- they have non-diabetic hyperglycaemia (defined as a haemoglobin A1c level of 42 mmol/mol to 47 mmol/mol [6.0% to 6.4%] or a fasting plasma glucose level of 5.5 mmol/litre to 6.9 mmol/litre) **and**
- they have a high risk of cardiovascular disease based on risk factors such as hypertension and dyslipidaemia **and**
- it is prescribed in secondary care by a specialist multidisciplinary tier 3 weight management service **and**
- the company provides it according to the [commercial arrangement](#).

Background information including extracts from the NICE TA

- The manufacturer has confirmed that the commercial arrangement is only available through a trust (hospital) where there is a specialist tier 3 weight management service
- The clinical experts (In the NICE TA) explained that long-term weight loss would not be achieved without the ongoing and psychological support that is a feature of tier 3 services.
- Locally tier 3 weight management services are provided by Luton and Dunstable Hospital.
- Liraglutide (Saxenda®) is a different licensed product to liraglutide (Victoza®) and the doses of liraglutide (Saxenda®) used for weight management are different to that used in managing type 2 diabetes (Victoza®).
- Currently, all GLP-1 receptor analogue products apart from Saxenda® are NOT licensed as treatment options for weight management. Therefore apart from Saxenda® (in line with the NICE TA) all other GLP-1 receptor agonists are NOT RECOMMENDED as a treatment for weight management.

Refer to Summary of Product Characteristics for further information <http://www.medicines.org.uk/emc/>